. doi: 10.1016/j.virs.2024.01.004
Citation: Lin Cheng, Liuqing Yang, Miao Wang, Yabo Peng, Haiyan Wang, Xiaoxiang Yang, Juanjuan Zhao, Mingxia Zhang, Fuxiang Wang, Zheng Zhang. Isolation and characterization of mpox virus from the first mpox case in Shenzhen, China .VIROLOGICA SINICA, 2024, 39(2) : 335-337.  http://dx.doi.org/10.1016/j.virs.2024.01.004

深圳首例患者体内猴痘病毒的分离和鉴定

  • 猴痘病毒在包括中国在内的全球范围内的快速传播,凸显制定抗病毒策略的重要意义。由于缺乏猴痘病毒的临床分离株,国内主要使用痘苗病毒对开发的新型抗病毒药物和疫苗进行测试。在此,我们报道了深圳分离的第一株猴痘病毒毒株hMpxV/China/SZ-SZTH42/2023(简称SZTH42)。将来自患者的qPCR阳性皮肤疱疹液接种Vero E6细胞单层,培养72小时内出现典型的噬斑。通过病毒基因组二代测序证实为猴痘病毒。在系统发育上,分离株SZTH42属于分支IIb的C.1谱系,代表了目前世界范围内流行的IIb分支菌株。免疫荧光检测显示分离株SZTH42与市售痘苗病毒诱导的多克隆抗体发生交叉反应。在此基础上,分别开发了用于病毒滴定的焦点形成试验(Focus Forming Assay,FFA)和中和活性评估的和焦点减少中和试验(Focus-Reduction Neutralization Test,FRNT)。通过FFA测定SZTH42的复制动力学,结果显示感染后48小时的病毒滴度最高,释放的细胞外包膜病毒的比例显著低于细胞相关包膜病毒。通过FRNT方法评估了5名猴痘患者的血浆对MPXV SZTH42分离物的中和活性。总之,本研究成功分离了猴痘病毒,为深入研究MPXV的特征以及抗病毒药物和疫苗的开发提供了关键资源和技术平台。

Isolation and characterization of mpox virus from the first mpox case in Shenzhen, China

  • Highlights
    1. We reported the first MPXV strain hMpxV/China/SZ-SZTH42/2023 isolated in southern China.
    2. The isolate SZTH42 belongs to C.1 lineage of clade IIb, representing the currently prevalent IIb branch strain worldwide.
    3. This study provides key resources and technical platforms for further research as well as antiviral drugs and vaccines development.

  • 加载中
    1. Gong Q, Wang C, Chuai X, Chiu S. 2022. Monkeypox virus:A re-emergent threat to humans. Virol Sin, 37:477-482.

    2. Huang B, Zhao H, Song J, Zhao L, Deng Y, Wang W, Lu R, Wang W, Ren J, Ye F, Tian H, Wu G, Ling H, Tan W. 2022. Isolation and characterization of monkeypox virus from the first case of monkeypox-chongqing municipality, china, 2022. China CDC Wkly, 4:1019-1024.

    3. Jia H, Sha T, Zhao S, Su W, Liu P, Zhen R, Li P, Zhou L, Xu Y, Wen Y, Chi L, Di B, Li P, Chen H, Qin P. 2023. Genomic and epidemiological perspectives on the first local sporadic cases of mpox in china. Emerg Microbes Infect, 12:2245932.

    4. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L. 2020. Human neutralizing antibodies elicited by sars-cov-2 infection. Nature, 584:115-119.

    5. Li M, Ren Z, Wang Y, Jiang Y, Yang M, Li D, Chen J, Liang Z, Lin Y, Zeng Z, Xu R, Wang Y, Zhu L, Xiao W, Wu Q, Zhang B, Wan C, Yang Y, Wu B, Peng J, Zhao W, Shen C. 2023. Three neutralizing mabs induced by mpxv a29l protein recognizing different epitopes act synergistically against orthopoxvirus. Emerg Microbes Infect, 12:2223669.

    6. Lustig S, Fogg C, Whitbeck JC, Moss B. 2004. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology, 328:30-35.

    7. Payne LG. 1979. Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus. J Virol, 31:147-155.

    8. Russo AT, Grosenbach DW, Chinsangaram J, Honeychurch KM, Long PG, Lovejoy C, Maiti B, Meara I, Hruby DE. 2021. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther, 19:331-344.

    9. Sun S, Cai Y, Song TZ, Pu Y, Cheng L, Xu H, Sun J, Meng C, Lin Y, Huang H, Zhao F, Zhang S, Gao Y, Han JB, Feng XL, Yu DD, Zhu Y, Gao P, Tang H, Zhao J, Zhang Z, Yang J, Hu Z, Fu YX, Zheng YT, Peng H. 2021. Interferon-armed rbd dimer enhances the immunogenicity of rbd for sterilizing immunity against sars-cov-2. Cell Res, 31:1011-1023.

    10. Yang L, Chen Y, Li S, Zhou Y, Zhang Y, Pei R, Chen X, Wang Y. 2023. Immunization of mice with vaccinia virus tiantan strain yields antibodies cross-reactive with protective antigens of monkeypox virus. Virol Sin, 38:162-164.

    11. Zhang RR, Wang ZJ, Zhu YL, Tang W, Zhou C, Zhao SQ, Wu M, Ming T, Deng YQ, Chen Q, Jin NY, Ye Q, Li X, Qin CF. 2023. Rational development of multicomponent mrna vaccine candidates against mpox. Emerg Microbes Infect, 12:2192815.

    12. Zhou B, Wang H, Cheng L, Zhao C, Zhou X, Liao X, Ge X, Liu L, Lu X, Ju B, Zhang Z. 2023. Two long-lasting human monoclonal antibodies cross-react with monkeypox virus a35 antigen. Cell Discov, 9:50.

  • 加载中
  • 10.1016j.virs.2024.01.004-ESM.doc

Article Metrics

Article views(461) PDF downloads(8) Cited by(0)

Related
Proportional views
    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Isolation and characterization of mpox virus from the first mpox case in Shenzhen, China

      Corresponding author: Fuxiang Wang, wangfuxiang999@163.com
      Corresponding author: Zheng Zhang, zhangzheng1975@aliyun.com
    • a. Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, 518112, China;
    • b. Department of Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen 518112, China;
    • c. The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, China

    Abstract: Highlights
    1. We reported the first MPXV strain hMpxV/China/SZ-SZTH42/2023 isolated in southern China.
    2. The isolate SZTH42 belongs to C.1 lineage of clade IIb, representing the currently prevalent IIb branch strain worldwide.
    3. This study provides key resources and technical platforms for further research as well as antiviral drugs and vaccines development.

    Reference (12) Relative (20)

    目录

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return